Indonesia clears its first generic Ceftazidime plus Avibactam, opening a new market for Venus Remedies

Saransh Chaudhary, President Global Critical Care at Venus Remedies and CEO of Venus Medicine Research Centre, and Aditi K. Chaudhary, President International Business, outline the significance of the approval

Mumbai, January 15, 2026: Indonesia has cleared its first generic version of the critical antibiotic combination Ceftazidime plus Avibactam, following the grant of marketing authorisation to Venus Remedies Limited by the country’s regulatory authority. The approval marks the company’s first anti-infective marketing authorisation in Indonesia and signals a significant expansion of its presence in Southeast Asia.
The clearance enables the first generic entry of Ceftazidime plus Avibactam in the Indonesian market, strengthening access to advanced hospital-based therapies used to treat serious multidrug-resistant bacterial infections. For Venus Remedies, the milestone represents a key regulatory and commercial step as it expands beyond oncology into anti-infective therapies within the country.

Indonesia is among the largest pharmaceutical markets in Southeast Asia, where antibiotics remain a critical therapeutic category due to the burden of infectious diseases and growing emphasis on antimicrobial stewardship. The approval also aligns with Venus Remedies’ broader strategy to deepen its footprint across ASEAN markets, where the company is commercially active in ten countries and holds more than 370 injectable approvals.
Commenting on the development, Saransh Chaudhary, President Global Critical Care at Venus Remedies and Chief Executive Officer of Venus Medicine Research Centre, said the approval reflects the company’s continued focus on addressing antimicrobial resistance through clinically relevant therapies designed for hospital care. He noted that the milestone reinforces Venus Remedies’ commitment to expanding access to life-saving anti-infective treatments in international markets.

Ceftazidime plus Avibactam is indicated for the treatment of serious infections such as complicated intra-abdominal infections and complicated urinary tract infections caused by gram-negative pathogens, including Pseudomonas aeruginosa and Enterobacteriaceae. Avibactam works by inhibiting key beta-lactamase enzymes, restoring the effectiveness of ceftazidime against resistant bacterial strains.
Aditi K. Chaudhary, President International Business at Venus Remedies, said the approval marks the company’s entry into the anti-infective segment in Indonesia, a priority market within its international growth plans. She added that the development reflects a long-term approach to building a compliant, scalable, and sustainable business in the region.

The broader ASEAN pharmaceutical market is projected to exceed USD 63.5 billion by 2029, underlining its strategic importance for Indian pharmaceutical exports. As the first generic of its kind to be introduced in Indonesia, Ceftazidime plus Avibactam is expected to improve access to advanced anti-infective therapy in hospital and critical-care settings, while strengthening Venus Remedies’ commercial platform across Southeast Asia.

At Prittle PrattleNews, featuring you virtuously, we celebrate the commitment and innovation. Led by Editor-in-Chief Smruti Bhalerao, our platform is dedicated to sharing impactful stories that inspire change and create awareness. Follow us on LinkedIn, Instagram, and YouTube for more stories that matter.